Bryan Johnson Announces Cloning of Newborn Version Using His Own Cells
Bryan Johnson announced the cloning of a newborn version using his own cells, currently placed in a petri dish, which can serve as his own blood child, test therapies, cultivate organs, and develop new treatments.
The process includes drawing blood to extract cells, applying Yamanaka factors to reset epigenetic age, allowing the cells to regain pluripotency, and differentiating into neurons, cardiomyocytes, etc., for reconstructing body organs.
The longevity pioneer advances personalized regenerative medicine through autologous cell technology, with funding directed towards stem cell and anti-aging research, benefiting Bryan Johnson's projects and related biotech companies, while ethicists express concerns about potential risks.
Source: Public Information
ABAB AI Insight
Bryan Johnson has previously invested heavily in personalized anti-aging through the Blueprint project, similar to his public plasma exchanges and extreme dietary interventions, which attracted attention and propelled the biohacking community's development.
In terms of capital pathways, self-cloning technology mobilizes private funding to support cutting-edge stem cell research while providing data for clinical trials, accelerating the transition from laboratory to personalized medicine.
Similar to the early application of iPS cell technology discovered by Yamanaka in regenerative medicine, the anti-aging field is currently transitioning from symptom management to cellular reprogramming.
This essentially represents a technological substitution, where epigenetic resetting breaks the accumulation of age-related damage, pushing healthcare from external interventions to autologous reconstruction, reshaping the capital pathways of the longevity industry and human maintenance models.
ABAB News · Cognitive Laws
Autologous cells have no rejection, reconstruction has no limits.
Epigenetic errors are reversible, aging is not destiny.
Self-cloning is self-investment, maximizing health returns.